Abstract
Median NLR was 2.55 (IQR: 1.90-3.62) Patients with NLR <3 were older (74.45 vs. 67.94; p1⁄40.02) and exhibited significant differences in term of pathological stage (p1⁄40.03) and no. of tumours (p1⁄40.04) if compared with those with NLR 3. During the follow-up study, 14 (23.3%) and 44 (37.9%) (p1⁄40.04) patients respectively with NLR <3 and 3 experienced recurrence and 2 (3.3%) and 14 (11.9%) experienced progression (p1⁄40.06). At the multivariate Cox regression analysis, NLR < 3 was associated with low disease recurrence (HR: 0.34 [IQR: 0.17-0.68]; p<0.01). Pathological stage pT1 (p<0.01), high grade (p<0.01), no. of tumours (p<0.01) and smoking status (p<0.01) were independently predictors of disease recurrence. No association was found between NLR 3 and disease progression at the multivariate Cox regression analysis. The 5 years recurrence free survival was 49% and 62% in patients with NLR 3 and < 3 (p1⁄40.04). The 5 year progression free survival was 77% and 93% in patients with NLR 3 and < 3 (p1⁄40.69). CONCLUSIONS: NLR is an independent predictor of disease recurrence but no of progression in patients with newly diagnosed NMIBC. These findings could offer a new contribution to find new biomarkers of recurrence in NMIBC patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
